臨床婦人科産科74巻3号

2020年04月発行

今月の臨床 徹底解説！ 卵巣がんの最新治療―複雑化する治療を整理する

新規治療薬の作用機序と使いどころ《分子標的薬・免疫チェックポイント阻害薬》

VEGF阻害薬の作用機序と使いどころ

著者： 馬淵誠士¹ 山田有紀¹ 岩井加奈¹

所属機関： ¹奈良県立医科大学産科婦人科学教室

ページ範囲：P.325 - P.333

文献概要

●抗VEGF-A中和抗体であるベバシズマブは，①血管新生の阻害，②既存の微小血管の退縮，③腫瘍血管の正常化を引き起こすため，単剤より抗がん剤との併用で強い効果を発揮する．

●ベバシズマブは，術後補助化学療法や再発がんに対する治療において無増悪生存期間を延長するだけでなく，腹水の産生抑制を通じてQOLの改善にも寄与しうる薬剤である．

●ベバシズマブを用いた術前化学療法やベバシズマブと他の分子標的治療薬の併用効果を検討する臨床試験，また効果を予見するバイオマーカーの開発を目指した研究が進行中である．

参考文献

1）Folkman J : Tumor angiogenesis : therapeutic implications. N Engl J Med 285 : 1182-1186, 1971

2）Gerber HP, et al : Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65 : 671-680, 2005

3）Duncan TJ, et al : Vascular endothelial growth factor expression in ovarian cancer : a model for targeted use of novel therapies? Clin Cancer Res 14 : 3030-3035, 2008

4）Mabuchi S, et al : VEGF is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther 9 : 2411-2422, 2010

5）Burger RA, et al : Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365 : 2473-2483, 2011

6）Tewari KS, et al : Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol 37 : 2317-2328, 2019

7）Perren TJ, et al : A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365 : 2484-2496, 2011

8）Chan JK, et al : Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 374 : 738-748, 2016

9）Walker JL, et al : Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma : an NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol 37 : 1380-1390, 2019

10）the U.S. National Institutes of Health : ClinicalTrials.gov. NCT01837251. http://clinicaltrials.gov

11）Aghajanian C, et al : OCEANS : a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30 : 2039-2045, 2012

12）Coleman RL, et al : Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer（NRG Oncology/Gynecologic Oncology Group study GOG-0213） : a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18 : 779-791, 2017

13）Pfisterer J, et al : 9330. Carboplatin/pegylated liposomal doxorubicin/bevacizumab（CD-BEV）vs. carboplatin/gemcitabine/bevacizumab（CG-BEV）in patients with recurrent ovarian cancer : A prospective randomized phase III ENGOT/GCIG-Intergroup study（AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG）. Ann Oncol 29（suppl 8）: viii332-viii358, 2018

14）Pignata S, et al : Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment : the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. J Clin Oncol 36（suppl） : 5506, 2018

15）Pujade-Lauraine E, et al : Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer : The AURELIA open-label randomized phase III trial. J Clin Oncol 32 : 1302-1308, 2014

16）UMIN Clinical Trials Registry : UMIN000017247. https://www.umin.ac.jp/ctr/index.htm

17）Garcia Garcia Y, et al : Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer. Int J Gynecol Cancer 29 : 1050-1056, 2019

18）Numnum TM, et al : The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 102 : 425-428, 2006

19）Oza AM, et al : Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer（ICON7）: overall survival results of a phase 3 randomised trial. Lancet Oncol 16 : 928-936, 2015

20）González Martín A, et al : Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecol Oncol 152 : 53-60, 2019

21）Sorio R, et al : Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer : subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol 144 : 65-71, 2017

22）Komiyama S, et al : Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer : a prospective observational study of safety and efficacy in Japanese patients（JGOG3022 trial）. Int J Clin Oncol 24 : 103-114, 2019

23）Norquist BM, et al : Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218 : an NRG Oncology/Gynecologic Oncology Group study. Clin Cancer Res 24 : 777-783, 2018

24）Kommoss S, et al : Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes. Clin Cancer Res 23 : 3794-3801, 2017

25）Tanyi JL, et al : Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol 120 : 464-469, 2011

26）Burger RA, et al : Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer : a Gynecologic Oncology Group study. J Clin Oncol 32 : 1210-1217, 2014

27）Cannistra SA, et al : Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25 : 5180-5186, 2007

28）Saif MW, et al : Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14 : 1860-1869, 2007

29）Kabbinavar FF, et al : Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer : results from a large treatment observational cohort study. Eur J Cancer 48 : 1126-1132, 2012

30）Tewari KS, et al : Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370 : 734-743, 2014

31）Tew WP, et al : Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma : An NRG oncology/gynecologic oncology group study. Gynecol Oncol 151 : 257-263, 2018

32）Mirza MR, et al : Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer : A randomized controlled chemotherapy-free study―NSGO-AVANOVA2/ENGOT-OV24. J Clin Oncol 37（suppl）: 5505, 2019

33）the U.S. National Institutes of Health : ClinicalTrials.gov. NCT02477644. http://clinicaltrials.gov

34）the U.S. National Institutes of Health : ClinicalTrials.gov. NCT03038100. http://clinicaltrials.gov

35）the U.S. National Institutes of Health : ClinicalTrials.gov. NCT02891824. http://clinicaltrials.gov

36）the U.S. National Institutes of Health : ClinicalTrials.gov. NCT02839707. http://clinicaltrials.gov